Thai L P, Moss J R, Godman B, Vitry A I
a Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute , University of South Australia , Adelaide , South Australia , Australia.
b School of Public Health , University of Adelaide , Adelaide , South Australia , Australia.
Expert Rev Pharmacoecon Outcomes Res. 2016 Jun;16(3):419-33. doi: 10.1586/14737167.2016.1136790. Epub 2016 Feb 2.
The Australian Pharmaceutical Benefits Scheme (PBS) provides universal access to subsidized medicines. In 2013, statins as a class had the highest expenditure on the PBS.
To assess the influence of policies and drivers affecting PBS statin utilization and expenditure between 1992 and 2013.
Analyses conducted from 1992 to 2013 and over three distinct time periods, including monthly expenditure/prescription, annual utilization (calculated as Defined Daily Doses/1000 inhabitants/day) and statin strengths dispensed.
The major driver of increased PBS expenditure for statins was increased volumes. After adjusting for inflation, the average PBS expenditure on statin prescriptions was the major negative driver. Other influential drivers included the increased use of newer statins and increased strength of statins dispensed.
Whilst the inflation-adjusted reimbursed price of statins decreased, increased utilization, including increased use of patented statins, increased total statin expenditure. Successful measures adopted by other countries could be applied to Australia to decrease total medicines expenditure.
澳大利亚药品福利计划（PBS）提供了获得补贴药品的普遍途径。2013年，他汀类药物作为一个类别在PBS上的支出最高。
评估1992年至2013年间影响PBS他汀类药物使用和支出的政策及驱动因素。
分析涵盖1992年至2013年以及三个不同时间段，包括每月支出/处方量、年使用量（以限定日剂量/1000居民/天计算）和所配发他汀类药物的强度。
PBS他汀类药物支出增加的主要驱动因素是用量增加。在调整通胀因素后，他汀类药物处方的平均PBS支出是主要的负面驱动因素。其他有影响的驱动因素包括新型他汀类药物使用增加以及所配发他汀类药物强度增加。
虽然经通胀调整后的他汀类药物报销价格下降，但使用量增加，包括专利他汀类药物使用增加，导致他汀类药物总支出增加。其他国家采取的成功措施可应用于澳大利亚以降低药品总支出。
